| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 27, 2023 |
| Accession Number: | 0001493152-23-008803 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 27, 2023 |
| Accession Number: | 0001493152-23-008803 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 10/6/2021 | $5.00 | Buy | HC Wainwright & Co. |
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer. Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history of scientific innovation and program leadership at the int
SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)
SC 13G - Vyant Bio, Inc. (0001349929) (Subject)
SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou FoundationEntered into a master services agreement and related statement of work with an Australian CRO in November 2022 to support the Company's adult Rett Syndrome clinical trialProgress with licensing our iPSC technology to transition key product sales customers Q3 2022 Financial Highlights $9.4 million of cash and equivalents as of September 30, 2022Current cash balances, net proceeds from the sale of
~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology's Capabilities to Provide Customers with Solutions in Both the Discovery and Development of New Drug Candidates ~ ~ Transaction Provides Vyant Bio with Additional Capital to Deploy into Further Development of its Therapeutic Pipeline in Genetic CNS Disorders ~ MALVERN, PA and CHERRY HILL, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reaction Biology Corporation ("Reaction"), an industry-leading provider of drug discovery services, and Vyant Bio, Inc. ("Vyant Bio") (NASDAQ:VYNT), an innovative biotechnology company reinventing drug
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 million of cash and equivalents as of June 30, 2022Cash runway approximately 18 months CHERRY HILL, N.J., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (N
HC Wainwright & Co. reiterated coverage of Vyant Bio with a rating of Buy and set a new price target of $4.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Vyant Bio with a rating of Buy and set a new price target of $5.00
PRE 14A - Vyant Bio, Inc. (0001349929) (Filer)
15-12G - Vyant Bio, Inc. (0001349929) (Filer)
8-K - Vyant Bio, Inc. (0001349929) (Filer)
CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company's stock will cease trading on the OTC, and the holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, purs
CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company's common stock will cease to trade and holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at the date we file the Certificate of Dissolution to receive dist
CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the "Special Meeting"). At the Special Meeting, Vyant Bio's stockholders, upon the unanimous recommendation of Vyant Bio's board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the "Dissolution Proposal). The proposal received the affirmative vote of holders of 94.0% of the shares casting votes and 53.1% of the Company's total outstanding common shares. Vyant Bio's Board will determin
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares increased by 68.4% to $3.25 during Friday's pre-market session. The market value of their outstanding shares is at $2.7 million. The company's, Q1 earnings came out yesterday. ARS Pharmaceuticals (NASDAQ:SPRY) shares moved upwards by 53.93% to $6.96. The market value of their outstanding shares is at $657.3 million. Athenex (NASDAQ:ATNX) shares rose 20.68% to $1.4. The market value of their outstanding shares is at $12.1 million. ABVC BioPharma (NASDAQ:ABVC) stock increased by 14.49% to $0.89. The market value of their outstanding shares is at $29.5 million. Babylon Holdings (NYSE:BBLN) shares moved upwards by 14.28% to $1.36. The compan
Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. As previously announced, Vyant Bio filed a Form 25 with the Securities and Exchange Commission (the "SEC") on May 4, 2023 to voluntary delist its securities from The Nasdaq Capital Market ("Nasdaq"). Today, Vyant Bio announced that, following the effectiveness of the Form 25 and the delisting
Gainers Sunshine Biopharma, Inc. (NASDAQ:SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. VCI Global Limited (NASDAQ:VCIG) shares jumped 63.6% to $5.32. VCI Global reported application for dual listing on Upstream. Polar Power, Inc. (NASDAQ:POLA) jumped 63.5% to $1.6847 after the company unveiled new line of mobile electric vehicle chargers. Jaguar Health, Inc. (NASDAQ:JAGX) rose 47.2% to $1.06. Canalevia-CA1, Jaguar Animal Health's FDA conditionally approved drug for chemotherapy-induced diarrhea in dogs, is now available from Chewy. Minim, Inc. (NASDAQ:MINM) gained 33% to $6.14. Absolute Software Corporation (NASDAQ:ABST) shares gained 32.3% to $11.36 after the co